GlassScriptPhysician profile
Lalithkumar K Chouhan
NPI 1124011028
$11,167.00
in general payments reported to CMS, 2019-2025
35 companies · $2,502 in 2025
The $2,502 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $855 · 2021: $1,738 · 2022: $1,682 · 2023: $1,303 · 2024: $2,217 · 2025: $2,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,939 · Travel and Lodging: $1,017 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,938.87 |
| Travel and Lodging | $1,017.11 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,792.55 | 2019-2025 | |
| Biotronik INC. | $1,217.78 | 2022-2025 | Selectra |
| Merck Sharp & Dohme LLC | $719.89 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $698.11 | 2019-2025 | Farxiga, Brilinta |
| Kestra Medical Technology Services, INC. | $680.53 | 2023-2025 | Assure Wcd |
| Abiomed | $680.22 | 2021-2024 | Impella |
| Janssen Pharmaceuticals, INC | $616.62 | 2019-2024 | Xarelto |
| Pfizer INC. | $514.85 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $435.40 | 2019-2025 | Jardiance |
| Amgen INC. | $434.74 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $430.18 | 2019-2025 | Amplatzer Amulet, Jot Dx, Aveir |
| E.R. Squibb & Sons, L.L.C. | $389.83 | 2019-2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $337.62 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $332.02 | 2019-2025 | Lifevest |
| Cvrx, INC. | $271.31 | 2021-2025 | Barostim Neo System |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $247.82 | 2024-2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $208.79 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.23 | 2021-2024 | |
| Impulse Dynamics (USA) INC. | $186.08 | 2022-2024 | Optimizer |
| Medtronic, INC. | $148.37 | 2021-2023 | Micra |
| Scpharmaceuticals INC. | $88.28 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $86.74 | 2020-2021 | |
| Lundbeck LLC | $70.05 | 2019-2020 | |
| Astellas Pharma US INC | $64.99 | 2023 | |
| Novo Nordisk INC | $53.29 | 2024-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $49.68 | 2021-2024 | Watchman Access System |
| Esperion Therapeutics, INC. | $40.79 | 2020-2021 | |
| Medtronic Vascular, INC. | $33.17 | 2019 | |
| Vifor Pharma, INC. | $30.18 | 2020-2021 | |
| Davol INC. | $28.65 | 2025 | Arista |
| Kiniksa Pharmaceuticals International, Plc | $23.00 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $21.11 | 2023 | Inspire |
| Lexicon Pharmaceuticals, INC. | $19.02 | 2024 | |
| Irhythm Technologies, INC. | $11.87 | 2019 | |
| Braemar Manufacturing, LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalithkumar Chouhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.